| Size | Price | |
|---|---|---|
| Other Sizes |
Purity: ≥98%
| Targets |
Benfluorex targets hepatocyte nuclear factor 4α (HNF4α) as an activator. It decreases the relative rate of hepatic triacylglycerol synthesis as an antilipidemic agent. It was used for the treatment of poorly controlled type 2 diabetes. The compound was never approved in some countries due to safety concerns including pulmonary hypertension and valvular disease.
|
|---|---|
| ln Vitro |
Benfluex regularly increases the amount of GFP-positive cells, a marker of insulin promoter activity. In a dose-dependent manner, benfluex raises endogenous insulin mRNA levels and the number of GFP-positive cells. In line with its role as an HNF4α activator, Benfluex induces the expression of HNF4α. HNF4α protease sensitivity is changed by benfluex, but not by inactive control molecules [1]. Benfluex greatly increases the generation of 14CO2 in the citric acid cycle while decreasing the synthesis of ketone bodies and acid-soluble metabolites in oleic acid in a concentration-dependent way. Benfluex reduces lactate/pyruvate (10/1 nM) gluconeogenesis rate in a dose-dependent manner [2].
In vitro, benfluorex acts as an HNF4α activator. It shows antilipidemic activity by decreasing the relative rate of hepatic triacylglycerol synthesis. No specific IC50 or EC50 values are provided in the available literature. The compound has been used in research on diabetes and lipid metabolism. |
| ln Vivo |
In vivo, benfluorex (brand name Mediator) was used clinically as an anorectic and antilipidemic agent for the treatment of poorly controlled type 2 diabetes. It was associated with serious adverse effects including pulmonary hypertension and valvular disease. The compound was never approved in some countries.
|
| Enzyme Assay |
Cell-free HNF4α activation assays for benfluorex typically involve measuring its ability to activate HNF4α transcriptional activity. Standard protocols include incubation of HNF4α protein with a fluorescein-labeled coactivator peptide and the compound at concentrations of 0.01-1000 µM in assay buffer (50 mM Tris-HCl pH 7.4, 50 mM KCl, 1 mM DTT) at 25°C. Fluorescence polarization is measured to determine the EC50 for activation. Alternatively, cell-free transcription assays using HNF4α response element-driven reporter constructs can be performed.
|
| Cell Assay |
In vitro cell-based assays for benfluorex involve treatment of hepatocyte cell lines (e.g., HepG2) with the compound at concentrations of 0.1-100 µM for 24-72 hours. HNF4α activation is assessed by measuring expression of HNF4α target genes (e.g., apolipoproteins, gluconeogenic enzymes) by qPCR. Lipid metabolism is assessed by measuring triglyceride synthesis and secretion. Cell viability is assessed by MTT or LDH assay. Antidiabetic activity is assessed by measuring glucose production.
|
| Animal Protocol |
In vivo animal protocols for benfluorex involve administration to rodent models of diabetes or hyperlipidemia via oral gavage at doses of 1-50 mg/kg. Blood glucose and lipid profiles are measured. For toxicology studies, administration to rodents for assessment of pulmonary hypertension and valvular disease. Pharmacokinetic parameters are determined from serial blood samples analyzed by LC-MS/MS.
|
| References |
[1]. Lee SH, et al. Identification of alverine and benfluorex as HNF4α activators. ACS Chem Biol. 2013 Aug 16;8(8):1730-6.
[2]. Kohl C, et al. Effects of benfluorex on fatty acid and glucose metabolism in isolated rat hepatocytes: from metabolic fluxes to gene expression. Diabetes. 2002 Aug;51(8):2363-8 |
| Additional Infomation |
2-[1-[3-(trifluoromethyl)phenyl]propyl-2-ylamino]ethyl benzoate is a benzoic acid ester. Benfluorex is an anorexic and lipid-lowering drug with a structure related to fenfluramine. It is patented and manufactured by the French pharmaceutical company Servier. The European Medicines Agency (EMA) recommended a recall of all medicines containing benfluorex on December 18, 2009. This recommendation was based on the risk (especially cardiovascular side effects similar to fenfluramine) outweighing the benefits. Benfluorex is a lipid-lowering drug that reduces the rate of triglyceride synthesis in the liver. Benfluorex has never been approved for use in the United States and was recalled in the European Union due to the increased risk of pulmonary hypertension and valvular disease. See also: Benfluorex hydrochloride (note moved here).
|
| Molecular Formula |
C19H20F3NO2
|
|---|---|
| Molecular Weight |
386.8158
|
| Exact Mass |
387.121
|
| CAS # |
23602-78-0
|
| Related CAS # |
Benfluorex hydrochloride;23642-66-2
|
| PubChem CID |
2318
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.183g/cm3
|
| Boiling Point |
420.5ºC at 760 mmHg
|
| Flash Point |
208.1ºC
|
| Vapour Pressure |
2.81E-07mmHg at 25°C
|
| Index of Refraction |
1.515
|
| LogP |
5.275
|
| tPSA |
38.33
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
25
|
| Complexity |
408
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(CC1=CC(=CC=C1)C(F)(F)F)NCCOC(=O)C2=CC=CC=C2
|
| InChi Key |
CJAVTWRYCDNHSM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H20F3NO2/c1-14(12-15-6-5-9-17(13-15)19(20,21)22)23-10-11-25-18(24)16-7-3-2-4-8-16/h2-9,13-14,23H,10-12H2,1H3
|
| Chemical Name |
2-((1-(3-(trifluoromethyl)phenyl)propan-2-yl)amino)ethyl benzoate
|
| Synonyms |
BRN 4152887 JP 992 SE 780 Minolip Mediator EINECS 245-777-9 Benfluramate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5852 mL | 12.9259 mL | 25.8518 mL | |
| 5 mM | 0.5170 mL | 2.5852 mL | 5.1704 mL | |
| 10 mM | 0.2585 mL | 1.2926 mL | 2.5852 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00544518 | UNKNOWN STATUS | Drug: metformin Drug: benfluorex |
Type 2 Diabetes | Air Force Military Medical University, China | 2007-10 | Phase 2 |
| NCT02008552 | COMPLETED | Genetic: Sampling of blood | Blood Sample | University Hospital, Brest | 2013-10-18 | Not Applicable |
| NCT06107322 | RECRUITING | Neutropenia | University Hospital, Strasbourg, France | 2023-03-01 |
|
|
|